Cancer antigen 125: Lost to follow-up? A European Society of Gynaecological Oncology consensus statement

International Journal of Gynecological Cancer

Volumn 22, Issue 1, 2012, Pages 170-174

  Verheijen, René H M ^a   Cibula, David ^b   Zola, Paolo ^c   Reed, Nicolas ^d  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b CHARLES UNIVERSITY   (Czech Republic)

^c MAURIZIANO HOSPITAL   (Italy)

^d BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

Author keywords

CA 125; Follow up; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN;

ANTIGEN DETECTION; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SCINTISCANNING; CANCER SURVIVAL; CONSENSUS DEVELOPMENT; CYTOREDUCTIVE SURGERY; FOLLOW UP; HUMAN; HYPERTHERMIC THERAPY; MEDICAL SOCIETY; OVARY CANCER; PATIENT MONITORING; PHOTON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW;

CA-125 ANTIGEN; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; QUALITY OF LIFE;

EID: 84858217607     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e318226c636     Document Type: Review

References (25)

1. Bast RC Jr, Klug TL, St. John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309:883-887. (Pubitemid 13014028)
2. Rustin GJ, van der Burg ME, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010;376:1155-1163.
3. Goonewardene TI, Hall MR, Rustin GJS. Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations. Lancet Oncol. 2007;8:813-821. (Pubitemid 47308670)
4. Rustin GJ, Nelstrop AE, Crawford M, et al. Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA 125. J Clin Oncol. 1997;15:172-176. (Pubitemid 27020570)
5. Crawford SM, Peace J. Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary? Ann Oncol. 2005;16:47-50. (Pubitemid 40124477)
6. Verheijen RH, von Mensdorff-Pouilly S, van Kamp GJ, et al. CA 125: fundamental and clinical aspects. Semin Cancer Biol. 1999;9:117-124. (Pubitemid 29265527)
7. Prat A, Parera M, Adamo B, et al. Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low level increase of serum CA-125 levels. Ann Oncol. 2009;20:294-297.
8. Santillan A, Garg R, Zahurak ML, et al. Risk of epithelial ovarian cancer recurrence in patients with rising serum CA-125 levels within the normal range. J Clin Oncol. 2005;23:9338-9343.
9. Rustin GJ, Nelstrop AE, Tuxen MK, et al. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol. 1996;7:361-364. (Pubitemid 26246787)
10. Harter P, du Bois A, Hahmann M, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006;13:1702-1710. (Pubitemid 44951480)
11. Harter P, Hahmann M, Lueck HJ, et al. Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I Trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann Surg Oncol. 2009;16:1324-1330.
12. Oksefjell H, Sandstad B, Tropé C. The role of secondary cytoreduction in the management of the first relapse in epithelial ovarian cancer. Ann Oncol. 2009;20:286-293.
13. Zang RY, Li ZT, Tang J, et al. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits? Cancer. 2004;100:1152-1161. (Pubitemid 38325942)
14. Parker PA, Kudelka A, Basen-Engquist K, et al. The associations between knowledge, CA125 preoccupation, and distress in women with epithelial ovarian cancer. Gynecol Oncol. 2006;100:495-500. (Pubitemid 43246864)
15. Hipkins J, Whitworth M, Tarrier N, et al. Social support, anxiety and depression after chemotherapy for ovarian cancer: a prospective study. Br J Health Psychol. 2004;9:569-581. (Pubitemid 39487264)
16. Vermorken JB. Second-line randomized trials in epithelial ovarian cancer. Int J Gynecol Cancer. 2008; 18:59-66. (Pubitemid 351395240)
17. Benedetti Panici P, De Vivo A, Bellati F, et al. Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer. Ann Surg Oncol. 2007;14: 1136-1142.
18. Bristow RE, del Carmen MG, Pannu HK, et al. Clinically occult recurrent ovarian cancer: patient selection for secondary cytoreductive surgery using combined PET/CT. Gynecol Oncol. 2003;90:519-528.
19. Shah CA, Lowe KA, Paley P, et al. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125. Cancer Epidemiol Biomarkers Prev. 2009;18:1365-1372.
20. Gu P, Pan LL, Wu SQ, et al. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta- analysis. Eur J Radiol. 2009;71:164-174.
21. Crijns APG, Fehrmann RSN, de Jong S, et al. Survival-related profile, pathways, and transcription factors in ovarian cancer. PLoS Med. 2009;6:e24.
22. Spannuth WA, Sood AK, Coleman RL. Farletuzumab in epithelial ovarian carcinoma. Expert Opin Biol Ther. 2010;10:431-437.
23. Han ES, Burger RA, Darcy KM, et al. Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer. Gynecol Oncol. 2010;119:484-490.
24. Markman M, Brady M, Hutson A, et al. Survival after second-line intraperitoneal therapy for the treatment of epithelial ovarian cancer: the Gynecologic Oncology Group experience. Int J Gynecol Cancer. 2009;19:223-229.
25. Hopkins ML, Coyle D, Le T, et al. Cancer antigen 125 in ovarian cancer surveillance: a decision analysis model. Curr Oncol. 2007;14:167-172.